These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28651617)

  • 21. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.
    Pylkäs K; Erkko H; Nikkilä J; Sólyom S; Winqvist R
    BMC Cancer; 2008 May; 8():146. PubMed ID: 18501021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.
    Janavičius R; Rudaitis V; Mickys U; Elsakov P; Griškevičius L
    Cancer Genet; 2014 May; 207(5):195-205. PubMed ID: 25066507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptome Patterns of
    Arakelyan A; Melkonyan A; Hakobyan S; Boyarskih U; Simonyan A; Nersisyan L; Nikoghosyan M; Filipenko M; Binder H
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.
    Cao WM; Gao Y; Yang HJ; Xie SN; Ding XW; Pan ZW; Ye WW; Wang XJ
    BMC Cancer; 2016 Feb; 16():64. PubMed ID: 26852015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
    Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
    Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic testing in hereditary breast and ovarian cancer using massive parallel sequencing.
    Ruiz A; Llort G; Yagüe C; Baena N; Viñas M; Torra M; Brunet A; Seguí MA; Saigí E; Guitart M
    Biomed Res Int; 2014; 2014():542541. PubMed ID: 25136594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.
    Simard J; Dumont M; Moisan AM; Gaborieau V; Malouin H; Durocher F; Chiquette J; Plante M; Avard D; Bessette P; Brousseau C; Dorval M; Godard B; Houde L; ; Joly Y; Lajoie MA; Leblanc G; Lépine J; Lespérance B; Vézina H; Parboosingh J; Pichette R; Provencher L; Rhéaume J; Sinnett D; Samson C; Simard JC; Tranchant M; Voyer P; Easton D; Tavtigian SV; Knoppers BM; Laframboise R; Bridge P; Goldgar D
    J Med Genet; 2007 Feb; 44(2):107-21. PubMed ID: 16905680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Ion Personal Genome Machine Platforms for the Detection of Variants in
    Hwang SM; Lee KC; Lee MS; Park KU
    Cancer Res Treat; 2018 Jan; 50(1):255-264. PubMed ID: 28392550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
    Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA-analyzer: Automatic workflow for processing NGS reads of BRCA1 and BRCA2 genes.
    Kechin A; Khrapov E; Boyarskikh U; Kel A; Filipenko M
    Comput Biol Chem; 2018 Dec; 77():297-306. PubMed ID: 30408727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
    Machackova E; Claes K; Mikova M; Házová J; Sťahlová EH; Vasickova P; Trbusek M; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2019; 32(Supplementum2):51-71. PubMed ID: 31409081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
    El Saghir NS; Zgheib NK; Assi HA; Khoury KE; Bidet Y; Jaber SM; Charara RN; Farhat RA; Kreidieh FY; Decousus S; Romero P; Nemer GM; Salem Z; Shamseddine A; Tfayli A; Abbas J; Jamali F; Seoud M; Armstrong DK; Bignon YJ; Uhrhammer N
    Oncologist; 2015 Apr; 20(4):357-64. PubMed ID: 25777348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of an NGS Approach for Diagnostic BRCA1/BRCA2 Mutation Testing.
    Dacheva D; Dodova R; Popov I; Goranova T; Mitkova A; Mitev V; Kaneva R
    Mol Diagn Ther; 2015 Apr; 19(2):119-30. PubMed ID: 25893891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
    Melki R; Melloul M; Aissaoui S; El Harroudi T; Boukhatem N
    BMC Cancer; 2023 Apr; 23(1):339. PubMed ID: 37055759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
    Vošmiková H; Ryška A; Sieglová K; Laco J
    Cesk Patol; 2016; 52(4):210-214. PubMed ID: 27869447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.